Notably, two of the targets addressed—BCL-2 and mutant IDH1—are individually validated in AML therapy, as evidenced by recent FDA approvals of Venetoclax (BCL-2 inhibitor) and Ivosidenib/Olutasidenib (IDH1 inhibitors) for AML subsets [27]. Here, IDH1 is linked to acute myeloid leukemia.